Audited Financial Results for the 4th Quarter and Year ended 31.03.2026
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vimta Labs reported strong full-year results with total income growing 19.5% to ₹4,162.79 million from ₹3,482.22 million in FY25. Revenue from operations increased 18.4% to ₹4,072.90 million. Profit before tax rose 15% to ₹1,039.53 million while profit after tax from continuing operations grew 16% to ₹775.12 million. The company generated robust operating cash flow of ₹1,471.42 million, up from ₹940.54 million in the prior year. EPS from continuing operations stood at ₹17.20. The Board recommended dividend of ₹2 per share (100% payout on face value). The company also announced plans to set up a wholly-owned subsidiary in the USA and completed sale of its diagnostic business to Thyrocare in October 2024.
Solid double-digit revenue and profit growth with clean audit opinion signals fundamental business strength. Strong cash generation reduces debt concerns while the USA expansion plan indicates growth ambition. Dividend payout provides near-term shareholder returns.